Source comparison
MK-677 FAQ: Dosing Comparison
Researchers frequently ask how MK-677 compares to other growth hormone modulating compounds in terms of dosing, administration, and practical laboratory use. The following table summarizes key differences: MK-677 (Ibutamoren) 12.5–25mg daily Oral (powder/capsu
This comparison does not assign a generated winner or score.
- Researchers frequently ask how MK-677 compares to other growth hormone modulating compounds in terms of dosing, administration, and practical laboratory use. The following table summarizes key differences:
- MK-677 (Ibutamoren)
- 12.5–25mg daily
- Oral (powder/capsule)
- Once daily
- ~24 hours
- Room temp stable, seal from moisture
- Most convenient for long-duration studies; oral dosing eliminates injection variables
- Ipamorelin
- 200–300mcg per dose
- Subcutaneous injection
- 2–3× daily
- ~2 hours
- Refrigerate 2–8°C after reconstitution
- Requires multiple daily dosing; peptide handling protocols mandatory
- Sermorelin
- 200–500mcg per dose
- Once daily (bedtime)
- ~10 minutes
- Extremely short half-life limits experimental window; precise timing critical
- CJC-1295 (No DAC)
- 100–200mcg per dose
- ~30 minutes
- Synergistic with GHRP compounds; often stacked with Ipamorelin in research
- CJC-1295 (with DAC)
- 2mg weekly
- Once weekly
- ~6–8 days
- Extended half-life reduces dosing frequency but may cause non-physiological GH elevation
- MK-677's oral bioavailability and 24-hour half-life make it the least labor-intensive option for chronic administration studies. Peptide-based secretagogues require reconstitution with bacteriostatic water, refrigerated storage, and multiple daily injections. Variables that introduce handling complexity and increase contamination risk in long-term protocols.